AngioLab Profile

A biotechnology company specialized in angiogenesis

Established in 1999 and awarded numerous Korean government-research grants

Possesses more than 60 international and domestic patents

Developing products based on angiogenesis inhibitors

Field of Business

  • AL101-AOB (Abdominal obesity)

  • AL101-AMD (Age-related macular degeneration)

  • AL101-NASH (Non alcoholic steatohepatitis)

  • AL102-PDT (Periodontitis)

  • AL101-OME (Otitis media with effusion)

  • AL101-PSO (Psoriasis)

  • AL201-AB (Antibody)

  • Ob-X (Health functional food with proven claims of visceral fat reduction)